FREE SHIPPING over $40
OVER 9000 FIVE-STAR REVIEWS
5% OFF ALL SUBSCRIPTIONS
100% HAPPINESS GUARANTEE
Analyze Diet
0
Home / Equine Research Bank / J Pharm Anal / Enhancing the dissolution of phenylbutazone using Syloid&#xA...
Journal of pharmaceutical analysis2018; 8(3); 181-186; doi: 10.1016/j.jpha.2018.01.004

Enhancing the dissolution of phenylbutazone using Syloid® based mesoporous silicas for oral equine applications.

Abstract: Three mesoporous silica excipients (Syloid® silicas AL-1 FP, XDP 3050 and XDP 3150) were formulated with a model drug known for its poor aqueous solubility, namely phenylbutazone, in an attempt to enhance the extent and rate of drug dissolution. Although other forms of mesoporous silica have been investigated in previous studies, the effect of inclusion with these specific Syloid® silica based excipients and more interestingly, with phenylbutazone, is unknown. This work reports a significant enhancement for both the extent and rate of drug release for all three forms of Syloid® silica at a 1:1 drug:silica ratio over a period of 30 min. An explanation for this increase was determined to be conversion to the amorphous form and an enhanced drug loading ability within the pores. Differences between the release profiles of the three silicas were concluded to be a consequence of the physicochemical differences between the three forms. Overall, this study confirms that Syloid® silica based excipients can be used to enhance dissolution, and potentially therefore bioavailability, for compounds with poor aqueous solubility such as phenylbutazone. In addition, it has been confirmed that drug release can be carefully tailored based on the choice of Syloid® silica and desired release profile.
Get Full Text
Publication Date: 2018-01-31 PubMed ID: 29922487PubMed Central: PMC6004617DOI: 10.1016/j.jpha.2018.01.004Google Scholar: Lookup
The Equine Research Bank provides access to a large database of publicly available scientific literature. Inclusion in the Research Bank does not imply endorsement of study methods or findings by Mad Barn.
LinkedInCopy
  • Journal Article

Summary

This research summary has been generated with artificial intelligence and may contain errors and omissions. Refer to the original study to confirm details provided. Submit correction.

The research explored how the dissolution and release of phenylbutazone, a drug with poor solubility in water, could be improved when incorporated into mesoporous silicas derived from Syloid®. The results showed significant enhancement in both the extent and rate of the drug’s dissolution when using all three types of Syloid® silicas.

Introduction

  • The study focused on improving the rate of dissolution and the extent of the formulation of phenylbutazone, a drug known for its weak solubility in water. This was achieved by incorporating the drug in mesoporous silica excipients derived from Syloid® namely AL-1 FP, XDP 3050, and XDP 3150.
  • The goal was to understand if and how these excipients could impact the drug’s performance, as the effects of these specific silicas on phenylbutazone have not been studied before.

Experiment and Results

  • The researchers found a substantial improvement in both the rate at which the drug was released and the amount of drug released from the formulation when using the three types of Syloid® silicas at a 1:1 drug:silica ratio over 30 minutes.
  • The observed increase in dissolution was attributed to the conversion of the drug to its amorphous form, as well as the increased ability to load the drug within the pores of the silicas.
  • The differences in drug release profiles among the three types of silica were attributed to the different physical and chemical properties of these silicas.

Conclusion

  • The study validates that Syloid® silica-based excipients can be used to enhance the dissolution and potentially the bioavailability of drugs with poor solubility in water, such as phenylbutazone.
  • The research also confirmed that the release of the drug can be carefully controlled and tailored depending on the choice of Syloid® silica and the desired release profile, opening up a new means of optimizing drug delivery.

Cite This Article

APA
Waters LJ, Hanrahan JP, Tobin JM, Finch CV, Parkes GMB, Ahmad SA, Mohammad F, Saleem M. (2018). Enhancing the dissolution of phenylbutazone using Syloid® based mesoporous silicas for oral equine applications. J Pharm Anal, 8(3), 181-186. https://doi.org/10.1016/j.jpha.2018.01.004

Publication

Journal of pharmaceutical analysis
ISSN: 2214-0883
NlmUniqueID: 101579451
Country: China
Language: English
Volume: 8
Issue: 3
Pages: 181-186

Researcher Affiliations

Waters, Laura J
  • School of Applied Sciences, University of Huddersfield, Queensgate, Huddersfield HD1 3DH, UK.
Hanrahan, John P
  • Glantreo Ltd, ERI Building, Lee Road, Cork City T23 XE10, Ireland.
Tobin, Joseph M
  • Glantreo Ltd, ERI Building, Lee Road, Cork City T23 XE10, Ireland.
Finch, Catherine V
  • School of Applied Sciences, University of Huddersfield, Queensgate, Huddersfield HD1 3DH, UK.
Parkes, Gareth M B
  • School of Applied Sciences, University of Huddersfield, Queensgate, Huddersfield HD1 3DH, UK.
Ahmad, Shamsí·®n A
  • School of Applied Sciences, University of Huddersfield, Queensgate, Huddersfield HD1 3DH, UK.
Mohammad, Faraj
  • School of Applied Sciences, University of Huddersfield, Queensgate, Huddersfield HD1 3DH, UK.
Saleem, Maria
  • School of Applied Sciences, University of Huddersfield, Queensgate, Huddersfield HD1 3DH, UK.

References

This article includes 33 references
  1. Choudhari Y, Hoefer H, Libanati C. Mesoporous silica drug delivery systems. 2014:665—693.
  2. Xu W, Riikonen J, Lehto VP. Mesoporous systems for poorly soluble drugs.. Int J Pharm 2013 Aug 30;453(1):181-97.
    pubmed: 22990124doi: 10.1016/j.ijpharm.2012.09.008google scholar: lookup
  3. Shen SC, Ng WK, Chia LS, Dong YC, Tan RB. Applications of mesoporous materials as excipients for innovative drug delivery and formulation.. Curr Pharm Des 2013;19(35):6270-89.
    pubmed: 23470004doi: 10.2174/1381612811319350005google scholar: lookup
  4. McCarthy CA, Ahern RJ, Dontireddy R, Ryan KB, Crean AM. Mesoporous silica formulation strategies for drug dissolution enhancement: a review.. Expert Opin Drug Deliv 2016;13(1):93-108.
    pubmed: 26549623doi: 10.1517/17425247.2016.1100165google scholar: lookup
  5. Cheng S.H., Liao W.N., Chen L.M.. pH-controllable release using functionalized mesoporous silica nanoparticles as an oral drug delivery system. J. Mater. Chem. 2011;21:7130–7137.
  6. Hu Y., Dong X., Ke L.. Polysaccharides/mesoporous silica nanoparticles hybrid composite hydrogel beads for sustained drug delivery. J. Mater. Sci. 2017;52:3095–3109.
  7. Wen H., Qiu Y.. Adsorption of small drug particles at the surface of large excipients. Pharm. Technol. Eur. 2006;18:39–44.
  8. Kiwilsza A., Pajzderska A., Mielcarek J.. Dynamical properties of nimodipine molecules confined in SBA-15 matrix. Chem. Phys. 2016;475:126–130.
  9. Murillo-Cremaes N., López-Periago A.M., Saurina J.. Nanostructured silica-based drug delivery vehicles for hydrophobic and moisture sensitive drugs. J. Supercrit. Fluids. 2013;73:34–42.
  10. Patil A., Chirmade U.N., Trivedi V.. Encapsulation of water insoluble drugs in mesoporous silica nanoparticles using supercritical carbon dioxide. J. Nanomed. Nanotechnol. 2011;2:111–119.
  11. Ahern RJ, Crean AM, Ryan KB. The influence of supercritical carbon dioxide (SC-CO2) processing conditions on drug loading and physicochemical properties.. Int J Pharm 2012 Dec 15;439(1-2):92-9.
    pubmed: 23041132doi: 10.1016/j.ijpharm.2012.09.047google scholar: lookup
  12. Kankala RK, Zhang YS, Wang SB, Lee CH, Chen AZ. Supercritical Fluid Technology: An Emphasis on Drug Delivery and Related Biomedical Applications.. Adv Healthc Mater 2017 Aug;6(16).
    pmc: PMC5849475pubmed: 28752598doi: 10.1002/adhm.201700433google scholar: lookup
  13. Choudhari Y., Reddy U., Monsuur F.. Comparative evaluation of porous silica based carriers for lipids and liquid drug formulations. Mesoporous Biomater. 2014;1:61–74.
  14. Monsuur F., Choudhari Y., Reddy U.. Solvent free amorphisation for pediatric formulations (minitablets) using mesoporous silica. Int. J. Pharm. 2016;511:1135–1136.
  15. Waters LJ, Hussain T, Parkes G, Hanrahan JP, Tobin JM. Inclusion of fenofibrate in a series of mesoporous silicas using microwave irradiation.. Eur J Pharm Biopharm 2013 Nov;85(3 Pt B):936-41.
    pubmed: 23954510doi: 10.1016/j.ejpb.2013.08.002google scholar: lookup
  16. McCarthy CA, Faisal W, O'Shea JP, Murphy C, Ahern RJ, Ryan KB, Griffin BT, Crean AM. In vitro dissolution models for the prediction of in vivo performance of an oral mesoporous silica formulation.. J Control Release 2017 Mar 28;250:86-95.
    pubmed: 28132935doi: 10.1016/j.jconrel.2016.12.043google scholar: lookup
  17. Kankala RK, Liu CG, Chen AZ, Wang SB, Xu PY, Mende LK, Liu CL, Lee CH, Hu YF. Overcoming Multidrug Resistance through the Synergistic Effects of Hierarchical pH-Sensitive, ROS-Generating Nanoreactors.. ACS Biomater Sci Eng 2017 Oct 9;3(10):2431-2442.
    pubmed: 33445301doi: 10.1021/acsbiomaterials.7b00569google scholar: lookup
  18. Kankala R.K., Kuthati Y., Liu C.L.. Killing cancer cells by delivering a nanoreactor for inhibition of catalase and catalytically enhancing intracellular levels of ROS. RSC Adv. 2015;5:86072–86081.
  19. Limnell T, Santos HA, Mäkilä E, Heikkilä T, Salonen J, Murzin DY, Kumar N, Laaksonen T, Peltonen L, Hirvonen J. Drug delivery formulations of ordered and nonordered mesoporous silica: comparison of three drug loading methods.. J Pharm Sci 2011 Aug;100(8):3294-3306.
    pubmed: 21520084doi: 10.1002/jps.22577google scholar: lookup
  20. Kinnari P, Mäkilä E, Heikkilä T, Salonen J, Hirvonen J, Santos HA. Comparison of mesoporous silicon and non-ordered mesoporous silica materials as drug carriers for itraconazole.. Int J Pharm 2011 Jul 29;414(1-2):148-56.
    pubmed: 21601623doi: 10.1016/j.ijpharm.2011.05.021google scholar: lookup
  21. Xu W, Riikonen J, Lehto VP. Mesoporous systems for poorly soluble drugs.. Int J Pharm 2013 Aug 30;453(1):181-97.
    pubmed: 22990124doi: 10.1016/j.ijpharm.2012.09.008google scholar: lookup
  22. Soma LR, Uboh CE, Maylin GM. The use of phenylbutazone in the horse.. J Vet Pharmacol Ther 2012 Feb;35(1):1-12.
    pubmed: 21668837doi: 10.1111/j.1365-2885.2011.01299.xgoogle scholar: lookup
  23. Castagnetti C., Mariella J.. Anti-inflammatory drugs in equine neonatal medicine. Part I: nonsteroidal anti-inflammatory drugs. J. Equine Vet. Sci. 2015;35:475–480.
  24. Sanchez LC, Robertson SA. Pain control in horses: what do we really know?. Equine Vet J 2014 Jul;46(4):517-23.
    pubmed: 24645799doi: 10.1111/evj.12265google scholar: lookup
  25. de Grauw JC, van Loon JP, van de Lest CH, Brunott A, van Weeren PR. In vivo effects of phenylbutazone on inflammation and cartilage-derived biomarkers in equine joints with acute synovitis.. Vet J 2014 Jul;201(1):51-6.
    pubmed: 24888681doi: 10.1016/j.tvjl.2014.03.030google scholar: lookup
  26. Domańska U, Pobudkowska A, Pelczarska A, Zukowski L. Modelling, solubility and pK(a) of five sparingly soluble drugs.. Int J Pharm 2011 Jan 17;403(1-2):115-22.
    pubmed: 21034801doi: 10.1016/j.ijpharm.2010.10.034google scholar: lookup
  27. Khan S, Batchelor H, Hanson P, Perrie Y, Mohammed AR. Physicochemical characterisation, drug polymer dissolution and in vitro evaluation of phenacetin and phenylbutazone solid dispersions with polyethylene glycol 8000.. J Pharm Sci 2011 Oct;100(10):4281-94.
    pubmed: 21560130doi: 10.1002/jps.22613google scholar: lookup
  28. Van Speybroeck M, Barillaro V, Thi TD, Mellaerts R, Martens J, Van Humbeeck J, Vermant J, Annaert P, Van den Mooter G, Augustijns P. Ordered mesoporous silica material SBA-15: a broad-spectrum formulation platform for poorly soluble drugs.. J Pharm Sci 2009 Aug;98(8):2648-58.
    pubmed: 19072861doi: 10.1002/jps.21638google scholar: lookup
  29. Longhofer SL, Reinemeyer CR, Radecki SV. Evaluation of the palatability of three nonsteroidal antiinflammatory top-dress formulations in horses.. Vet Ther 2008 Summer;9(2):122-7.
    pubmed: 18597250
  30. Hu Y, Wang J, Zhi Z, Jiang T, Wang S. Facile synthesis of 3D cubic mesoporous silica microspheres with a controllable pore size and their application for improved delivery of a water-insoluble drug.. J Colloid Interface Sci 2011 Nov 1;363(1):410-7.
    pubmed: 21820127doi: 10.1016/j.jcis.2011.07.022google scholar: lookup
  31. Guo Z, Liu XM, Ma L, Li J, Zhang H, Gao YP, Yuan Y. Effects of particle morphology, pore size and surface coating of mesoporous silica on Naproxen dissolution rate enhancement.. Colloids Surf B Biointerfaces 2013 Jan 1;101:228-35.
    pubmed: 23010024doi: 10.1016/j.colsurfb.2012.06.026google scholar: lookup
  32. Al-Oweini R., El-Rassy H.. Synthesis and characterization by FTIR spectroscopy of silica aerogels prepared using several Si(OR)4 and R′′Si(OR′)3 precursors. J. Mol. Struct. 2009;919:140–145.
  33. Martín A., García R.A., Karaman D.S.. Polyethyleneimine-functionalized large pore ordered silica materials for poorly water-soluble drug delivery. J. Mater. Sci. 2014;49:1437–1447.

Citations

This article has been cited 13 times.
  1. Szentmihályi K, Klébert S, May Z, Bódis E, Mohai M, Trif L, Feczkó T, Károly Z. Immobilization of Metronidazole on Mesoporous Silica Materials. Pharmaceutics 2022 Oct 29;14(11).
    doi: 10.3390/pharmaceutics14112332pubmed: 36365150google scholar: lookup
  2. Zhang W, Li G, Xiao C, Chang X, Sun Y, Fan W, Tian B, Gao D, Xiao Y, Wu X, He S, Zhai G. Mesoporous Silica Carrier-Based Composites for Taste-Masking of Bitter Drug: Fabrication and Palatability Evaluation. AAPS PharmSciTech 2022 Feb 15;23(2):75.
    doi: 10.1208/s12249-022-02227-7pubmed: 35169970google scholar: lookup
  3. Dadej A, Woźniak-Braszak A, Bilski P, Piotrowska-Kempisty H, Józkowiak M, Stawny M, Dadej D, Mrotek M, Jelińska A. APTES-Modified SBA-15 as a Non-Toxic Carrier for Phenylbutazone. Materials (Basel) 2022 Jan 26;15(3).
    doi: 10.3390/ma15030946pubmed: 35160897google scholar: lookup
  4. Ianni F, Gagliardi A, Taticchi A, Servili M, Pinna N, Schoubben A, Sardella R, Bruscoli S. Exploiting Food-Grade Mesoporous Silica to Preserve the Antioxidant Properties of Fresh Olive Mill Wastewaters Phenolic Extracts. Antioxidants (Basel) 2021 Aug 26;10(9).
    doi: 10.3390/antiox10091361pubmed: 34572992google scholar: lookup
  5. Kiss T, Katona G, Mérai L, Janovák L, Deák Á, Kozma G, Kónya Z, Ambrus R. Development of a Hydrophobicity-Controlled Delivery System Containing Levodopa Methyl Ester Hydrochloride Loaded into a Mesoporous Silica. Pharmaceutics 2021 Jul 7;13(7).
    doi: 10.3390/pharmaceutics13071039pubmed: 34371730google scholar: lookup
  6. Trzeciak K, Chotera-Ouda A, Bak-Sypien II, Potrzebowski MJ. Mesoporous Silica Particles as Drug Delivery Systems-The State of the Art in Loading Methods and the Recent Progress in Analytical Techniques for Monitoring These Processes. Pharmaceutics 2021 Jun 24;13(7).
    doi: 10.3390/pharmaceutics13070950pubmed: 34202794google scholar: lookup
  7. Shin HW, Kim JE, Park YJ. Nanoporous Silica Entrapped Lipid-Drug Complexes for the Solubilization and Absorption Enhancement of Poorly Soluble Drugs. Pharmaceutics 2021 Jan 6;13(1).
    doi: 10.3390/pharmaceutics13010063pubmed: 33418969google scholar: lookup
  8. Mehanna MM, Mneimneh AT, Domiati S, Allam AN. Tadalafil-Loaded Limonene-Based Orodispersible Tablets: Formulation, in vitro Characterization and in vivo Appraisal of Gastroprotective Activity. Int J Nanomedicine 2020;15:10099-10112.
    doi: 10.2147/IJN.S288552pubmed: 33363369google scholar: lookup
  9. Perez-Roman I, Kiekens F, Cordoba-Diaz D, Garcia-Rodriguez JJ, Cordoba-Diaz M. Development of a Solid Formulation Containing a Microemulsion of a Novel Artemisia Extract with Nematocidal Activity for Oral Administration. Pharmaceutics 2020 Sep 14;12(9).
    doi: 10.3390/pharmaceutics12090873pubmed: 32937773google scholar: lookup
  10. Al Tahan MA, Russell C, Al-Khattawi A. Mesoporous Silica Microparticle Tablets for Optimised Formulation and Overcoming Compressibility Challenges. Br J Biomed Sci 2025;82:14985.
    doi: 10.3389/bjbs.2025.14985pubmed: 41333280google scholar: lookup
  11. Al Tahan MA, Michaelides K, Somasekharan Nair S, AlShatti S, Russell C, Al-Khattawi A. Mesoporous Silica Microparticle-Protein Complexes: Effects of Protein Size and Solvent Properties on Diffusion and Loading Efficiency. Br J Biomed Sci 2024;81:13595.
    doi: 10.3389/bjbs.2024.13595pubmed: 39445315google scholar: lookup
  12. Moghadam RP, Shukla CA, Ranade VV. Novel Machine Learning-Based Method for Estimation of the Surface Area of Porous Silica Particles. Ind Eng Chem Res 2023 Nov 8;62(44):18810-18821.
    doi: 10.1021/acs.iecr.3c02785pubmed: 37969176google scholar: lookup
  13. Waters LJ, Whiteley J, Small W, Mellor S. Determining suitable surfactant concentration ranges to avoid protein unfolding in pharmaceutical formulations using UV analysis. Heliyon 2023 Nov;9(11):e21712.
    doi: 10.1016/j.heliyon.2023.e21712pubmed: 37954313google scholar: lookup
Subscribe to our newsletter
Join 99,344 horse owners like you who receive our email updates on horse health and nutrition.